IGM Biosciences (IGMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IGM Biosciences (IGMS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
IGM Biosciences, Inc. (IGMS) delivered earnings and revenue surprises of 4.72% and 31.47%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?